The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst
: Kiran ma'am, based on your comment that we will reassess the time line on the $1 billion target for biosimilars and the fact that we are focusing
on the business opportunities in emerging markets, should I read into this as U.S. and Europe will probably not contribute or not see a significant
ramp-up from here? Or let me put it this way, how should I look at the incremental ramp-up in the biosimilar revenue over the next year?
Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst
: And now what impacted the emerging market opportunity? Was it purely COVID? Or do you think there were certain issues internally that we need
to address, either by the way of logistics or capacity at the Biocon end?
Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst
: And on the margin trajectory for Biologics, as the revenue ramps up, when should we expect inflection in the margin profile of the Biologics
business? Or do you think that will probably be lower than the revenue ramp-up because of the investment?
Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst
: My question pertains to the biosimilars, excluding insulin. When do you see a market share ramp-up? Because in case of pegfilgrastim, there was
an approval from Express Scripts. So we expected a ramp-up from 2021. So how is that placed in the current situation? And secondly, I wanted to
know the loss on Malaysia.
Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst
: Whether the Malaysia breakeven has happened? Or is that also delayed?
| 
